Download PDF
Thromb Haemost 2014; 111(05): 996-1003
DOI: 10.1160/TH13-08-0663
New Technologies, Diagnostic Tools and Drugs
Schattauer GmbH

A novel H-FABP assay and a fast prognostic score for risk assessment of normotensive pulmonary embolism

Claudia Dellas
1   Department of Cardiology and Pneumology, Heart Center of the Georg August University of Göttingen, Germany
,
Merle Tschepe
1   Department of Cardiology and Pneumology, Heart Center of the Georg August University of Göttingen, Germany
,
Valerie Seeber
2   Center for Thrombosis and Hemostasis (CTH), University Medical Center Mainz, Johannes Gutenberg University of Mainz, Germany
,
Isabella Zwiener
2   Center for Thrombosis and Hemostasis (CTH), University Medical Center Mainz, Johannes Gutenberg University of Mainz, Germany
3   Institute for Medical Biostatistics, Epidemiology and Informatics, University Medical Center Mainz, Johannes Gutenberg University of Mainz, Germany
,
Katherina Kuhnert
1   Department of Cardiology and Pneumology, Heart Center of the Georg August University of Göttingen, Germany
,
Katrin Schäfer
1   Department of Cardiology and Pneumology, Heart Center of the Georg August University of Göttingen, Germany
4   Department of Cardiology and Angiology, University Medical Center Mainz, Johannes Gutenberg University of Mainz, Germany
,
Gerd Hasenfuß
1   Department of Cardiology and Pneumology, Heart Center of the Georg August University of Göttingen, Germany
,
Stavros Konstantinides
2   Center for Thrombosis and Hemostasis (CTH), University Medical Center Mainz, Johannes Gutenberg University of Mainz, Germany
,
Mareike Lankeit
1   Department of Cardiology and Pneumology, Heart Center of the Georg August University of Göttingen, Germany
2   Center for Thrombosis and Hemostasis (CTH), University Medical Center Mainz, Johannes Gutenberg University of Mainz, Germany
› Author Affiliations Financial support: The study was supported by a grant from the University of Göttingen (Heidenreich von Siebold Programme) to C.D. and a scholarship by the Südwestdeutsche Gesell-schaft für Innere Medizin to C.D. and M.L.. Furthermore, the study was supported by the Federal Ministry of Education and Research (BMBF 01EO1003). The authors are responsible for the contents of this publication.
Further Information

Publication History

Received: 12 August 2013

Accepted after major revision: 19 January 2013

Publication Date:
01 December 2017 (online)

    Permissions and Reprints

Summary

We tested whether heart-type fatty acid binding protein (H-FABP) measured by a fully-automated immunoturbidimetric assay in comparison to ELISA provides additive prognostic value in patients with pulmonary embolism (PE), and validated a fast prognostic score in comparison to the ESC risk prediction model and the simplified Pulmonary Embolism Severity Index (sPESI). We prospectively examined 271 normotensive patients with PE; of those, 20 (7%) had an adverse 30-day outcome. H-FABP levels determined by immunoturbidimetry were higher (median, 5.2 [IQR; 2.7–9.8] ng/ml) than those by ELISA (2.9 [1.1–5.4] ng/ml), but Bland-Altman plot demonstrated a good agreement of both assays. The area under the curve for H-FABP was greater for immunoturbidimetry than for ELISA (0.82 [0.74–0.91] vs 0.78 [0.68–0.89]; P=0.039). H-FABP measured by immunoturbidimetry (but not by ELISA) provided additive prognostic information to other predictors of 30-day outcome (OR, 12.4 [95% CI, 1.6–97.6]; P=0.017). When H-FABP determined by immunoturbidimetry was integrated into a novel prognostic score (H-FABP, Syncope, and Tachycardia; FAST score), the score provided additive prognostic information by multivariable analysis (OR, 14.2 [3.9–51.4]; p<0.001; c-index, 0.86) which were superior to information obtained by the ESC model (c-index, 0.62; net reclassification improvement (NRI), 0.39 [0.21–0.56]; P<0.001) or the sPESI (c-index, 0.68; NRI, 0.24 [0.05–0.43]; P=0.012). In conclusion, determination of H-FABP by immunoturbidimetry provides prognostic information superior to that of ELISA and, if integrated in the FAST score, appears more suitable to identify patients with an adverse 30-day outcome compared to the ESC model and sPESI.

 

  • References

  • 1 Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet 2012; 379: 1835-1846.
    CrossrefPubMedGoogle Scholar
  • 2 Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353: 1386-1389.
    CrossrefPubMedGoogle Scholar
  • 3 Laporte S, Mismetti P, Decousus H. et al. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry. Circulation 2008; 117: 1711-1716.
    CrossrefPubMedGoogle Scholar
  • 4 Pollack CV, Schreiber D, Goldhaber SZ. et al. Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry). J Am Coll Cardiol 2011; 57: 700-706.
    CrossrefPubMedGoogle Scholar
  • 5 Ng AC, Chung T, Yong AS. et al. Long-term cardiovascular and noncardiovascular mortality of 1023 patients with confirmed acute pulmonary embolism. Circ Cardiovasc Qual Outcomes 2011; 04: 122-128.
    CrossrefPubMedGoogle Scholar
  • 6 Torbicki A, Perrier A, Konstantinides S. et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008; 29: 2276-2315.
    CrossrefPubMedGoogle Scholar
  • 7 Apostolakis S, Konstantinides S. The Right Ventricle in Health and Disease: Insights into Physiology, Pathophysiology and Diagnostic Management. Cardiology 2012; 121: 263-273.
    CrossrefPubMedGoogle Scholar
  • 8 Sanchez O, Trinquart L, Colombet I. et al. Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: a systematic review. Eur Heart J 2008; 29: 1569-1577.
    CrossrefPubMedGoogle Scholar
  • 9 Becattini C, Agnelli G, Vedovati MC. et al. Multidetector computed tomography for acute pulmonary embolism: diagnosis and risk stratification in a single test. Eur Heart J 2011; 32: 1657-1663.
    CrossrefPubMedGoogle Scholar
  • 10 Klok FA, Mos IC, Huisman MV. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis. Am J Respir Crit Care Med 2008; 178: 425-430.
    CrossrefPubMedGoogle Scholar
  • 11 Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation 2007; 116: 427-433.
    CrossrefPubMedGoogle Scholar
  • 12 Jimenez D, Aujesky D, Moores L. et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 2010; 170: 1383-1389.
    CrossrefPubMedGoogle Scholar
  • 13 Aujesky D, Obrosky DS, Stone RA. et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 2005; 172: 1041-1046.
    CrossrefPubMedGoogle Scholar
  • 14 Puls M, Dellas C, Lankeit M. et al. Heart-type fatty acid-binding protein permits early risk stratification of pulmonary embolism. Eur Heart J 2007; 28: 224-229.
    CrossrefPubMedGoogle Scholar
  • 15 Kaczynska A, Pelsers MM, Bochowicz A. et al. Plasma heart-type fatty acid binding protein is superior to troponin and myoglobin for rapid risk stratification in acute pulmonary embolism. Clin Chim Acta 2006; 371: 117-123.
    CrossrefPubMedGoogle Scholar
  • 16 Dellas C, Puls M, Lankeit M. et al. Elevated heart-type fatty acid-binding protein levels on admission predict an adverse outcome in normotensive patients with acute pulmonary embolism. J Am Coll Cardiol 2010; 55: 2150-2157.
    CrossrefPubMedGoogle Scholar
  • 17 Boscheri A, Wunderlich C, Langer M. et al. Correlation of heart-type fatty acidbinding protein with mortality and echocardiographic data in patients with pulmonary embolism at intermediate risk. Am Heart J 2010; 160: 294-300.
    CrossrefPubMedGoogle Scholar
  • 18 Lankeit M, Friesen D, Schafer K. et al. A simple score for rapid risk assessment of non-highrisk pulmonary embolism. Clin Res Cardiol 2013; 102: 73-80.
    CrossrefPubMedGoogle Scholar
  • 19 Lankeit M, Jimenez D, Kostrubiec M. et al. Predictive value of the high-sensitivity troponin T assay and the simplified Pulmonary Embolism Severity Index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study. Circulation 2011; 124: 2716-2724.
    CrossrefPubMedGoogle Scholar
  • 20 Lankeit M, Friesen D, Aschoff J. et al. Highly sensitive troponin T assay in normotensive patients with acute pulmonary embolism. Eur Heart J 2010; 31: 1836-1844.
    CrossrefPubMedGoogle Scholar
  • 21 National Kidney Foundation. K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002; 39: S1-S000.
    PubMedGoogle Scholar
  • 22 Pencina MJ, D’Agostino Sr RB, D’Agostino RB. et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-172.
    CrossrefPubMedGoogle Scholar
  • 23 The PEITHO Steering Committee. Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury: rationale and design of the Pulmonary Embolism Thrombolysis (PEI-THO) trial. Am Heart J 2012; 163: 33-38.
    CrossrefPubMedGoogle Scholar
  • 24 Coutance G, Cauderlier E, Ehtisham J. et al. The prognostic value of markers of right ventricular dysfunction in pulmonary embolism: a meta-analysis. Crit Care 2011; 15: R103.
    CrossrefPubMedGoogle Scholar
  • 25 Kostrubiec M, Pruszczyk P, Bochowicz A. et al. Biomarker-based risk assessment model in acute pulmonary embolism. Eur Heart J 2005; 26: 2166-2172.
    CrossrefPubMedGoogle Scholar
  • 26 Jimenez D, Uresandi F, Otero R. et al. Troponin-based risk stratification of patients with acute nonmassive pulmonary embolism: systematic review and metaanalysis. Chest 2009; 136: 974-982.
    CrossrefPubMedGoogle Scholar
  • 27 Carless DR, Wnek M, Knox C. et al. Clinical and analytical evaluation of an im-munoturbidimetric heart-type fatty acid-binding protein assay. Scand J Clin Lab Invest 2013; 73: 48-53.
    CrossrefPubMedGoogle Scholar
  • 28 Viswanathan K, Kilcullen N, Morrell C. et al. Heart-type fatty acid-binding protein predicts long-term mortality and re-infarction in consecutive patients with suspected acute coronary syndrome who are troponin-negative. J Am Coll Cardiol 2010; 55: 2590-2598.
    CrossrefPubMedGoogle Scholar
  • 29 McMahon CG, Lamont JV, Curtin E. et al. Diagnostic accuracy of heart-type fatty acidbinding protein for the early diagnosis of acute myocardial infarction. Am J Emerg Med 2012; 30: 267-274.
    CrossrefPubMedGoogle Scholar
  • 30 Lankeit M, Konstantinides S. Is it time for home treatment of pulmonary embolism?. Eur Respir J 2012; 40: 742-749.
    CrossrefPubMedGoogle Scholar
  • 31 Aujesky D, Roy PM, Verschuren F. et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet 2011; 378: 41-48.
    CrossrefPubMedGoogle Scholar